TransMedics Group (NASDAQ:TMDX) Price Target Raised to $88.00

Key Points

• UBS raised its price target on TransMedics from $77 to $88 but maintained a neutral rating; the target implies 6.19% downside from the prior close. Analysts’ consensus rating is Hold, with an average target of $113.30.
• TransMedics reported quarterly EPS of $0.51, beating the $0.30 estimate, and revenue of $203.01 million versus $178.06 million expected. Revenue rose 41.1% year over year.
• The stock gained 6.3% on Monday to $93.80. Director David Weill also bought 1,336 shares at an average price of $81.63.

TransMedics Group (NASDAQ:TMDX - Get Free Report) had its target price upped by UBS Group from $77.00 to $88.00 in a research note issued on Monday, Benzinga reports. The firm currently has a "neutral" rating on the stock. UBS Group's price objective would suggest a potential downside of 6.19% from the company's previous close.

TMDX has been the subject of a number of other research reports. Piper Sandler reaffirmed an "overweight" rating and set a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, August 31st. Wall Street Zen raised shares of TransMedics Group from a "sell" rating to a "hold" rating in a research report on Saturday. TD Cowen reissued a "buy" rating and issued a $120.00 price objective on shares of TransMedics Group in a research report on Tuesday, September 8th. Finally, Canaccord Genuity Group increased their target price on shares of TransMedics Group from $95.00 to $120.00 and gave the stock a "buy" rating in a report on Friday. Five investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, TransMedics Group currently has an average rating of "Hold" and a consensus price target of $113.30.

TransMedics Group Stock Up 6.3%

Shares of TransMedics Group stock traded up $5.56 during trading on Monday, reaching $93.80. The stock had a trading volume of 1,364,041 shares, compared to its average volume of 1,020,811. The company has a current ratio of 4.53, a quick ratio of 4.15 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $3.24 billion, a price-to-earnings ratio of 25.42, a P/E/G ratio of 1.18 and a beta of 2.14. The stock has a fifty day moving average price of $79.61 and a two-hundred day moving average price of $93.17. TransMedics Group has a 52 week low of $60.10 and a 52 week high of $156.00.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.30 by $0.21. TransMedics Group had a return on equity of 13.30% and a net margin of 19.85%. The business had revenue of $203.01 million during the quarter, compared to the consensus estimate of $178.06 million. During the same period last year, the company earned $0.66 earnings per share. TransMedics Group's quarterly revenue was up 41.1% on a year-over-year basis. Sell-side analysts predict that TransMedics Group will post 1.50 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director David Weill purchased 1,336 shares of the company's stock in a transaction on Friday, September 11th. The shares were purchased at an average cost of $81.63 per share, with a total value of $109,057.68. Following the completion of the transaction, the director owned 16,392 shares of the company's stock, valued at $1,338,078.96. The trade was a 8.87% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Pinnacle Wealth Planning Services Inc. lifted its stake in TransMedics Group by 24.9% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 874 shares of the company's stock valued at $73,000 after purchasing an additional 174 shares during the last quarter. Plan A Wealth LLC increased its position in TransMedics Group by 3.9% during the third quarter. Plan A Wealth LLC now owns 5,370 shares of the company's stock worth $448,000 after buying an additional 203 shares during the last quarter. IFP Advisors Inc increased its position in TransMedics Group by 4.8% during the second quarter. IFP Advisors Inc now owns 4,652 shares of the company's stock worth $309,000 after buying an additional 213 shares during the last quarter. HB Wealth Management LLC increased its position in TransMedics Group by 1.5% during the second quarter. HB Wealth Management LLC now owns 15,062 shares of the company's stock worth $1,000,000 after buying an additional 219 shares during the last quarter. Finally, Bessemer Group Inc. raised its stake in TransMedics Group by 0.5% in the third quarter. Bessemer Group Inc. now owns 46,019 shares of the company's stock valued at $3,840,000 after buying an additional 220 shares during the period. Institutional investors own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services.

The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.